WINTON GROUP Ltd Decreases Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)

WINTON GROUP Ltd cut its position in Xencor, Inc. (NASDAQ:XNCR) by 3.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 53,705 shares of the biopharmaceutical company’s stock after selling 2,042 shares during the period. WINTON GROUP Ltd’s holdings in Xencor were worth $1,234,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares during the last quarter. KBC Group NV boosted its stake in Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 813 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its holdings in Xencor by 8.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 949 shares during the last quarter. Point72 DIFC Ltd increased its position in shares of Xencor by 10.9% during the third quarter. Point72 DIFC Ltd now owns 13,511 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 1,333 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,337 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on XNCR shares. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Wells Fargo & Company dropped their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Xencor presently has an average rating of “Moderate Buy” and a consensus target price of $34.38.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $11.51 on Friday. Xencor, Inc. has a 52 week low of $10.90 and a 52 week high of $27.24. The business’s 50 day moving average price is $15.72 and its 200 day moving average price is $20.14. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market cap of $811.02 million, a P/E ratio of -3.60 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. On average, sell-side analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.